Ascendis Pharma A/S filed a Form 6-K on November 6, 2026, reporting that the European Medicines Agency's Committee for Orphan Medicinal Products issued a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children.

Key Highlights

  • COMP positive opinion: The EMA's Committee for Orphan Medicinal Products adopted a positive opinion recommending maintenance of orphan medicinal product designation for TransCon CNP (navepegritide) for achondroplasia in children.
  • 10-year exclusivity potential: The designation would provide 10 years of orphan market exclusivity upon final adoption of the COMP opinion by the European Commission, according to the filing.
  • Prior CHMP opinion: The EMA's Committee for Medicinal Products for Human Use had previously issued a positive opinion recommending marketing authorization for TransCon CNP in the EU for achondroplasia in children two years of age and older whose epiphyses are not closed.
  • EC decision timeline: The company disclosed that the final European Commission decision on its Marketing Authorisation Application is expected during Q4 2026.
  • Planned Germany launch: If authorized by the EC, Ascendis expects its first EU launch of TransCon CNP under the brand name YUVIWEL to be in Germany during Q1 2027.

EMA Orphan Designation Opinion and EU Marketing Authorization Progress for TransCon CNP

According to the filing, on November 6, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced that the EMA's COMP adopted a positive opinion recommending maintenance of orphan medicinal product designation for once-weekly TransCon CNP (navepegritide) as a treatment for achondroplasia in children. The company disclosed that this designation would provide benefits including 10 years of orphan market exclusivity, contingent on final adoption of the COMP opinion by the European Commission.

The filing notes that the COMP opinion follows an earlier positive opinion from the EMA's CHMP, which recommended marketing authorization for once-weekly TransCon CNP in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final EC decision on Ascendis Pharma's Marketing Authorisation Application is expected during Q4 2026, the company disclosed.

The filing states that if authorized by the EC, Ascendis expects its first EU launch of TransCon CNP under the brand name YUVIWEL to be in Germany during Q1 2027. The filing includes forward-looking statements covering these anticipated timelines and regulatory outcomes, and the company noted that "actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements," citing factors including regulatory review risks, manufacturing risks, and market acceptance challenges, among others.

What Was Disclosed

Ascendis Pharma filed a Form 6-K on November 6, 2026, disclosing a positive COMP opinion for orphan medicinal product designation maintenance for TransCon CNP (navepegritide), a potential 10-year orphan market exclusivity benefit, an expected Q4 2026 EC decision on its MAA, and a planned Q1 2027 Germany launch under the YUVIWEL brand name.